Get the Stockscreener App
12.45
3.41%
-0.44
Generate Biomedicines Inc stock is traded at $12.45, with a volume of 119.56K.
It is down -3.41% in the last 24 hours and down -4.82% over the past month.
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.
See More
Previous Close:
$12.89
Open:
$12.9
24h Volume:
119.56K
Relative Volume:
0.46
Market Cap:
$1.58B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+4.27%
1M Performance:
-4.82%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$12.38
$13.06
1-Week Range:
$11.10
$13.36
52-Week Range:
$11.00
$14.21
Generate Biomedicines Inc Stock (GENB) Company Profile
Name
Generate Biomedicines Inc
Sector
Industry
Phone
-
Address
-
Compare GENB vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GENB
Generate Biomedicines Inc
|
12.43 | 1.64B | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
442.10 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
748.74 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
843.15 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
334.95 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
317.52 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Generate Biomedicines Inc Stock (GENB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-24-26 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-24-26 | Initiated | Goldman | Buy |
| Mar-24-26 | Initiated | Guggenheim | Buy |
| Mar-24-26 | Initiated | Morgan Stanley | Overweight |
| Mar-24-26 | Initiated | Piper Sandler | Overweight |
Generate Biomedicines Inc Stock (GENB) Latest News
Preferred dividends of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView — Track All Markets
GENB Forecast — Price Target — Prediction for 2027 - TradingView — Track All Markets
Generate Biomedicines, Inc. News — NASDAQ:GENB - TradingView — Track All Markets
Long term debt to total equity ratio of Generate Biomedicines, Inc. – BX:GENB - TradingView — Track All Markets
Preferred dividends of Generate Biomedicines, Inc. – BX:GENB - TradingView — Track All Markets
GENB Price Today: Generate Biomedicines, Inc. Stock Price, Quote & Chart | MEXC - MEXC
GENB Initiated Coverage by HC Wainwright & Co. -- Rating Set to Buy - GuruFocus
This Credo Technology Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
HC Wainwright Initiates Generate Biomedicines at Buy With $16 Price Target - marketscreener.com
IPO Tracker 2026: Seaport, Hemab set sail for Nasdaq - BioSpace
Severe Asthma Clinical Trial Pipeline Appears Robust With 30+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight | DelveInsight - GlobeNewswire Inc.
Top Generate Biomedicines (GENB) Competitors 2026 - MarketBeat
Cantor Fitzgerald reiterates Generate Biomedicines stock rating By Investing.com - Investing.com Canada
IPO Tracker 2026: Biotech Mega-Rounder Kailera Seeks IPO - BioSpace
Kailera Therapeutics files for US IPO - MarketScreener
Flagship-backed Generate Bio seeks $425 million in US IPO - MSN
Generate Biomedicines (NASDAQ:GENB) Rating Increased to Hold at Zacks Research - MarketBeat
Generate Biomedicines, Inc.Common Stock (Nasdaq:GENB) Stock Quote - FinancialContent
This KB Home Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday - Sahm
Generate Biomedicines gains buy initiations from Guggenheim, Piper Sandler - Seeking Alpha
The Goldman Sachs Group Initiates Coverage on Generate Biomedicines (NASDAQ:GENB) - MarketBeat
Morgan Stanley Initiates Coverage on Generate Biomedicines (NASDAQ:GENB) - marketbeat.com
Generate Biomedicines (NASDAQ:GENB) Coverage Initiated at Guggenheim - marketbeat.com
Generate Biomedicines (NASDAQ:GENB) Earns Overweight Rating from Analysts at Cantor Fitzgerald - MarketBeat
Goldman Sachs Initiates Coverage on Generate Biomedicines With Buy Rating, $26 Price Target - marketscreener.com
Guggenheim Initiates Coverage on Generate Biomedicines With Buy Rating, $30 Price Target - marketscreener.com
Piper Sandler initiates Generate Biomedicines stock at overweight By Investing.com - Investing.com Canada
Morgan Stanley Initiates Generate Biomedicines at Overweight With $20 Price Target - marketscreener.com
Morgan Stanley initiates Generate Biomedicines stock at overweight By Investing.com - Investing.com Canada
Piper Sandler initiates Generate Biomedicines stock at overweight - Investing.com
Morgan Stanley initiates Generate Biomedicines stock at overweight - Investing.com
Goldman Sachs initiates Generate Biomedicines stock with buy rating on AI platform potential - Investing.com
Guggenheim initiates Generate Biomedicines stock with buy rating By Investing.com - Investing.com Australia
Guggenheim initiates Generate Biomedicines stock with buy rating - investing.com
ETFs Investing in Generate Biomedicines, Inc. Stocks - TradingView — Track All Markets
Generate Biomedicines IPO Turns Heads - Yahoo! Finance Canada
Generate Biomedicines (GENB) Stock Trends and Sentiment 2026 - MarketBeat
Free cash flow per share of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
GENB | Generate Biomedicines, Inc. Common Stock Data, Price & News - Quiver Quantitative
Total debt per share of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Book value per share of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Revenue per share of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Generate Biomedicines (GENB) 10K Form and SEC Filings 2026 - MarketBeat
Total liabilities & shareholders' equities of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
After tax other income/expense of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Gross profit of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
EBIT of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Total revenue of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Average basic shares outstanding of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Cash per share of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Pretax income of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Generate Biomedicines Inc Stock (GENB) Financials Data
There is no financial data for Generate Biomedicines Inc (GENB). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Generate Biomedicines Inc Stock (GENB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Grous Beth | Chief People Officer |
Mar 02 '26 |
Buy |
16.00 |
300 |
4,800 |
300 |
| Silvers Jason | President & CFO |
Mar 02 '26 |
Buy |
16.00 |
2,000 |
32,000 |
1,000 |
| AFEYAN NOUBAR | Director |
Mar 02 '26 |
Buy |
16.00 |
4,687,500 |
75,000,000 |
15,264,724 |
| Mendillo Jane L | Director |
Mar 02 '26 |
Buy |
16.00 |
1,500 |
24,000 |
1,500 |
| AFEYAN NOUBAR | Director |
Mar 02 '26 |
Buy |
16.00 |
4,687,500 |
75,000,000 |
15,264,724 |
2.68%
0.34%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):